Takeda Accelerates Access to its Dengue Vaccine Through 'Make in India' Manufacturing Partnership with Biological E.

Takeda, a pharmaceutical company, has partnered with Biological E. Limited, a vaccines and biologics company in India, to manufacture Takeda's dengue vaccine, TAK-003. This partnership aims to combat the global public health threat of dengue fever and aligns with the World Health Organization's goal of achieving zero case-fatality rate due to dengue by 2030. The partnership will enhance manufacturing capabilities, potentially reaching 50 million doses annually and accelerating Takeda's efforts to manufacture 100 million doses annually within the decade. The vaccine has been approved in over 30 countries and has shown continued protection against dengue fever in long-term studies. [Extracted from the article]